JP2022553703A5 - - Google Patents

Info

Publication number
JP2022553703A5
JP2022553703A5 JP2022523575A JP2022523575A JP2022553703A5 JP 2022553703 A5 JP2022553703 A5 JP 2022553703A5 JP 2022523575 A JP2022523575 A JP 2022523575A JP 2022523575 A JP2022523575 A JP 2022523575A JP 2022553703 A5 JP2022553703 A5 JP 2022553703A5
Authority
JP
Japan
Prior art keywords
antigen
binding fragment
isolated antibody
approximately
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022523575A
Other languages
English (en)
Japanese (ja)
Other versions
JP7611908B2 (ja
JP2022553703A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/057635 external-priority patent/WO2021086899A1/en
Publication of JP2022553703A publication Critical patent/JP2022553703A/ja
Publication of JP2022553703A5 publication Critical patent/JP2022553703A5/ja
Application granted granted Critical
Publication of JP7611908B2 publication Critical patent/JP7611908B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022523575A 2019-10-28 2020-10-28 抗血球凝集素抗体およびその使用方法 Active JP7611908B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962926914P 2019-10-28 2019-10-28
US62/926,914 2019-10-28
US202063094170P 2020-10-20 2020-10-20
US63/094,170 2020-10-20
PCT/US2020/057635 WO2021086899A1 (en) 2019-10-28 2020-10-28 Anti-hemagglutinin antibodies and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022553703A JP2022553703A (ja) 2022-12-26
JP2022553703A5 true JP2022553703A5 (cg-RX-API-DMAC7.html) 2023-09-26
JP7611908B2 JP7611908B2 (ja) 2025-01-10

Family

ID=73498317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022523575A Active JP7611908B2 (ja) 2019-10-28 2020-10-28 抗血球凝集素抗体およびその使用方法

Country Status (13)

Country Link
US (2) US11773156B2 (cg-RX-API-DMAC7.html)
EP (1) EP4051707A1 (cg-RX-API-DMAC7.html)
JP (1) JP7611908B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220088446A (cg-RX-API-DMAC7.html)
CN (2) CN114761428B (cg-RX-API-DMAC7.html)
AU (2) AU2020374878B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022007923A2 (cg-RX-API-DMAC7.html)
CL (1) CL2022001067A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022005281A2 (cg-RX-API-DMAC7.html)
IL (1) IL292353A (cg-RX-API-DMAC7.html)
MY (1) MY207220A (cg-RX-API-DMAC7.html)
PH (1) PH12022550963A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021086899A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4508077A4 (en) 2022-04-14 2026-03-25 Invisishield Tech Ltd COMPOSITIONS FOR PREVENTING OR TREATMENT OF INFLUENZA INFECTIONS

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
JP6170507B2 (ja) * 2012-01-31 2017-07-26 国立大学法人大阪大学 B型インフルエンザウイルスに対する広範な保護を与えるヒトモノクローナル抗体及びその使用方法
HUE037659T2 (hu) * 2012-03-16 2018-09-28 Regeneron Pharma Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ennek az elõállítására
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
AU2015214146B2 (en) * 2014-02-04 2020-09-17 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
MX2016012530A (es) * 2014-03-27 2017-01-05 Genentech Inc Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso.
WO2016011035A2 (en) * 2014-07-15 2016-01-21 Medlmmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
TWI701258B (zh) * 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
MX389708B (es) * 2015-06-01 2025-03-20 Medimmune Llc Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
AU2016270147B2 (en) 2015-06-03 2018-08-23 Xiamen University Broad-spectrum monoclonal anti-flu B antibody and uses thereof
EP3471767A4 (en) * 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
WO2018187706A2 (en) * 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
SG11202006379UA (en) * 2018-01-26 2020-07-29 Regeneron Pharma Human antibodies to influenza hemagglutinin

Similar Documents

Publication Publication Date Title
JP6711828B2 (ja) インフルエンザ赤血球凝集素に対するヒト抗体
JP2018503361A5 (cg-RX-API-DMAC7.html)
JP2025172841A5 (cg-RX-API-DMAC7.html)
JP2022543612A5 (cg-RX-API-DMAC7.html)
RU2015136392A (ru) Композиции и способы, основанные на нейтрализующих антителах, доставляемых интраназально, для улучшенной терапевтической эффективности
JP2021511043A5 (cg-RX-API-DMAC7.html)
IL275884B2 (en) Human antibodies to influenza hemagglutinin
JP2024527607A5 (cg-RX-API-DMAC7.html)
JP2024149479A (ja) 黄熱を処置するための方法および組成物
CN102216330B (zh) 用于病毒所致的疾病的抗体药物组合物
JP2021523138A5 (cg-RX-API-DMAC7.html)
JP2023511956A5 (cg-RX-API-DMAC7.html)
CN116406274B (zh) 用于治疗冠状病毒的cd3抗体
AU2025271140A1 (en) Anti-hemagglutinin antibodies and methods of use thereof
JP2025501239A5 (cg-RX-API-DMAC7.html)
JP2024177399A (ja) 呼吸器疾患の治療のための汎elr+cxcケモカイン抗体
JP2019508458A5 (cg-RX-API-DMAC7.html)
JP2023538369A5 (cg-RX-API-DMAC7.html)
WO2016189491A1 (en) Novel formulation
EA046393B1 (ru) Антитела к гемагглютинину и их применение
NZ793707A (en) Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof